Ocular Therapeutix Sees FY23 DEXTENZA Net Product Revenue $55M-$60M Vs $59.05M Est.; Existing Cash And Cash Equivalents Of $66.6M As Of June 30, 2023
Portfolio Pulse from Happy Mohamed
Ocular Therapeutix expects FY23 DEXTENZA net product revenue to be between $55M-$60M, which represents a growth of 10% to 20% over 2022. The company's existing cash and cash equivalents as of June 30, 2023, are $66.6M, which is expected to fund operating expenses, debt service obligations, and capital expenditure requirements into 2025.
August 07, 2023 | 9:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix's FY23 revenue forecast for DEXTENZA is in line with estimates, indicating steady growth. The company's cash position is strong, expected to cover expenses into 2025.
The company's revenue forecast for DEXTENZA aligns with estimates, indicating a positive outlook for the product. The strong cash position provides financial stability, reducing the risk of liquidity issues in the near term. These factors are likely to have a positive impact on the stock in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100